Metabolic assessment in pure struvite stones formers: is it necessary?
Avaliação metabólica em formadores de cálculo de estruvita pura: é necessário?

ABSTRACT
Background and objective: Magnesium ammonium phosphate stones (MAP), also known as struvite stones, are associated with urinary infection and impairment of renal unit. The aim of this study is to evaluate the urinary metabolic risk factors for recurrence of renal calculi in patients submitted to nephrectomy due to MAP stones.
Methods: We retrospectively reviewed the charts of patients > 18 years old submitted to total nephrectomy due to pure MAP stones and pure calcium oxalate (CaOx) stones from July 2006 to July 2016. Urinary metabolic parameters were assessed through 24-hour urine exams \( \geq 3 \) months after nephrectomy. Urinary metabolic parameters and new event related to lithiasis were compared.
Results: Twenty-eight and 39 patients were included in MAP and CaOx group, respectively. Abnormalities in 24-hour urine samples were similar between groups. Hypercalciuria occurred in 7.1 and 10.3% of patients in MAP and CaOx group, respectively \( (p = 0.66) \), whereas hypocitraturia was present in 65.2 and 59.0% of patients with MAP and CaOx group, respectively \( (p = 0.41) \). No significant difference in new events was found between MAP and CaOx groups \( (17.9 \text{ vs. } 23.1\%), \text{ respectively; } p = 0.60 \). Conclusion: A 24-hour urine evaluation should be offered to patients submitted to nephrectomy due to pure MAP stones in order to detect metabolic risk, improve treatment, and prevent stone recurrence.

Keywords: Nephrectomy; Nephrolithiasis; Risk Factors; Struvite.

INTRODUCTION
Kidney stone incidence is rising worldwide and it has a recurrence rate of 50% at 5 years after the first episode.\(^1\) Magnesium ammonium phosphate stones (MAP), also known as
struvite stones, account for 5-15% of cases\(^4\). These stones are associated with the presence of urease-producing microorganisms, which hydrolyze urea and increase urinary pH, resulting in precipitation of MAP crystals\(^3\). Struvite stones can occupy the entire renal collecting system, resulting in infectious complications such as xanthogranulomatous pyelonephritis, pyonephrosis, perirenal abscess, and sepsis. In severe cases, these stones can cause renal function loss, associated with recurrent pain and urinary tract infection, and are treated by total nephrectomy\(^6\).

Nevertheless, other factors can be involved in struvite stone formation since urinary tract infection (UTI) caused by urease-producing bacteria not always produces struvite stones. In fact, other authors showed that the incidence of UTI caused by urease-positive bacteria was around 30% and the incidence of struvite stones was around 15\(^%\). On the other hand, patients with pure MAP stone may also present metabolic risk factors for renal calculi formation, such as hypercalciuria, hyperoxaluria, hypocitraturia, and hyperuricosuria, contributing to urolithiasis recurrence\(^8\).

The present study aimed to evaluate the incidence of urinary metabolic risk factors and its association with renal calculi recurrence after nephrectomy due to pure MAP stones.

**METHODS**

We performed a retrospective review of electronic medical records of patients > 18 years old submitted to nephrectomy due to pure MAP kidney stones in our institution from July 2006 to July 2016. In order to compare the results, we also reviewed data from patients who underwent nephrectomy due to calcium oxalate (CaOx) stones in the same period. Nephrectomy was indicated by loss of renal function associated with infectious complications such as recurrent urinary tract infection or pyonephrosis in the MAP group or loss of renal function associated with pain in the CaOx group. This study was approved by the Ethics Committee of our institution (research ethics board number: 15394).

Stone composition was determined by chemical analysis. Twenty-four-hour urine samples were collected ≥ 3 months after nephrectomy. The valid samples for inclusion contained urinary creatinine between 1,040 – 2,350 mg/24h for men and 740 – 1,570 mg/24h for women. Exclusion criteria were chronic renal failure stage 4 or 5, urinary tract infection during 24-hour urine collection, presence of contralateral urolithiasis and use of thiazide, citrate, or allopurinol during 24-hour urine collection.

Abnormal 24-hour urinary parameters used were as follows: hypercalciuria > 300 mg/24h of calcium excretion for men and > 250 mg/24h for women; hypocitraturia <320 mg/24h citrate excretion; hypernatriuria > 220 mEq/24h of sodium excretion; hyperoxaluria > 31 mg/24h oxalate excretion; hyperuricosuria > 800 mg/24h of uric acid excretion for men and > 750 mg/24h for women. Comorbidities were classified according to the Charlson comorbidity index\(^9\) and ASA (American Society of Anesthesiologists) classification\(^10\). Split renal function was evaluated by preoperative 99mTc-DMSA renal scan.

The metabolic abnormalities were addressed accordingly during follow-up. Patients with idiopathic hypercalciuria were treated with 50 mg/day thiazides titrated and patients with hypocitraturia were treated with potassium citrate with variable doses from 20 to 60 mEq/day depending on normal urinary citrate target and side effects. All patients underwent annual specialized medical consultation, serum creatinine evaluation, and ultrasonography (US) until the end of follow-up. Each new urinary stone found in US was confirmed by a computerized tomography. The occurrence of a new event related to lithiasis was defined as a new stone formation or stone elimination. The renal function was evaluated through chronic kidney disease epidemiology collaboration (CKD-EPI) equation\(^11\).

A multivariate logistic regression model was used to identify the urinary metabolic predictors of urolithiasis recurrence in the remaining kidney. The SPSS Advanced Statistics 24.0 program was used and the level of significance was defined as less than 5\%. 
**RESULTS**

Sixty-seven patients were included in this study (Table 1). Average follow-up was $71.6 \pm 30.8$ months in MAP group and $55.3 \pm 25.4$ months in CaOx group ($p = 0.28$).

The metabolic evaluation mean time was $18.3 \pm 12.7$ months. The frequency of abnormalities in 24-hour urine samples was similar between groups (Table 2). In the MAP group, 71.4% of patients had at least one metabolic abnormality compared to 66.6% in the CaOx group ($p = 0.67$). Hypercalciuria occurred in 7.1% and 10.3% of patients in MAP and CaOx groups, respectively ($p = 0.66$), whereas hypocitraturia was present in 65.2% and 59.0% of patients from MAP and CaOx groups, respectively ($p = 0.41$). No difference in hypocitraturia rate was observed between 1 and 2-3 CKD-EPI grades ($p = 0.45$).

No significant difference in new events between MAP and CaOx group (17.9 vs. 23.1%, respectively; $p = 0.60$) was found. The mean time to new event after nephrectomy was higher in the MAP group (66.8 ± 32.9 months vs. 50.3 ± 27.7 months, respectively; $p = 0.04$). Three patients from CaOx group and two from MAP group spontaneously passed stones during follow-up. Nine patients from CaOx group and five from MAP group formed new stones in the remained kidney. Stone analysis revealed calcium oxalate composition.

The risk for new event was not associated with the diagnosis of metabolic abnormalities in MAP group ($p = 0.36$) (Table 3). The actuarial curves of new event in MAP group with hypercalciuria, hypocitraturia, and hypernatriuria are shown in Figure 1, 2, and 3, respectively. The presence of urinary metabolic abnormalities did not influence the occurrence of new event in the MAP group (Table 1). Multivariate logistic regression of 24-hour urinary risk factors did not predict stone recurrence in the remaining kidney (Table 5).

**DISCUSSION**

We reported a high rate of 24-hour urine metabolic abnormalities in patients submitted to nephrectomy due to MAP stones. Stone recurrence rate was similar to CaOx stone formers (17.4 vs. 23.1%, $p=0.373$, respectively) in a long follow-up by annual ultrasound, confirmed by computerized tomography. We believe 24-hour urine analysis for patients who underwent nephrectomy by MAP stones is as important as for CaOx stones formers.

**Table 1**  DESCRIPTIVE ANALYSIS

|                | MAP (n=28) | CaOx (n=39) | p-value |
|----------------|------------|-------------|---------|
| Female         | 25 (89.2)  | 31 (79.4)   | 0.28    |
| Age (y)        | 48.8 ± 14.9| 51.8 ± 12.3 | 0.38    |
| BMI - mean/SD (kg/m²) | 26.47 | 27.51 | 0.77 |
| Mean arterial pressure - mean/SD (mmHg) | 9.5±2.1 | 9.8±1.7 | 0.6 |
| Follow up - mean/SD (m) | 71.6 ± 30.7 | 55.2 ± 25.3 | 0.28 |
| Charlson >2    | 6 (21.4)   | 14 (35.9)   | 0.2     |
| 1              | 11 (39.3)  | 8 (20.5)    |         |
| 2              | 12 (42.9)  | 28 (71.8)   |         |
| ASA            | 3          |             |         |
| 4              | 1 (3.6)    | 1 (2.6)     |         |
| 1              | 8 (28.6)   | 7 (17.9)    | 0.14    |
| Preoperative CKD-EPI | 2     | 19 (48.7)   | 0.74    |
| 3              | 9 (32.1)   | 13 (33.4)   |         |
| DMSA (affected kidney) % | 7.16 ± 8.79 | 6.94 ± 8.62 | 0.93 |
| Serum creatinine - mean/SD (mg/dL) | 0.9 ± 0.2 | 1.0 ± 0.2 | 0.28 |
| New event (yes) | 5 (179)    | 9 (23.1)    | 0.6     |

CaOx: calcium oxalate; MAP: magnesium ammonium phosphate; BMI: body mass index; ASA: American Society of Anesthesiologists; CKD EPI: Chronic Kidney Disease Epidemiology Collaboration; DMSA: technetium-99m dimercaptosuccinic acid.
Nephrolithiasis is a disease with a high recurrence rate, resulting in decreased quality of life and renal function loss in the long term\(^1\). A recent retrospective study evaluating 2,200 first-time urinary stone formers found a recurrence rate of 11, 20, 31, and 39% after 2, 5, 10, and 15 years\(^1\). Thus, treatment focused on stone formation prevention is crucial to decrease morbidity and costs. In addition, urinary lithiasis may contribute to the worsening of renal function in patients undergoing nephrectomy\(^1\).

Urinary stone formers are more likely to have urinary metabolic abnormalities than the healthy population\(^1\). Although metabolic assessment has been performed mainly for recurrent stone formers\(^1\), Eisner et al. did not find differences in urinary metabolic abnormalities between first-time patients and patients with recurrent calculi. These authors suggested that metabolic evaluation should be offered even to patients with urinary stone for the first time\(^1\). Patients with infection stones are considered to be at high risk for recurrence and should undergo metabolic assessment, as recommended by the European Urology Association\(^1\).

### Table 2

|                  | MAP (n=28)   | CaOx (n=39)  | p-value |
|------------------|--------------|--------------|---------|
| Volume – mean/SD (mL) | 1813.4 ± 367.2 | 1782.4 ± 591.9 | 0.82    |
| Hypercalciuria   | 7.1%         | 10.3%        | 0.66    |
| Hyperoxaluria    | 0            | 0            | 1.00    |
| Hypocitraturia   | 65.2%        | 59.0%        | 0.41    |
| Hyperuricosuria  | 13.0%        | 10.3%        | 0.52    |
| Hyperuricosuria  | 0            | 5.1%         | 0.39    |

CaOx: calcium oxalate; MAP: magnesium ammonium phosphate.

### Table 3

|                        | New event (R\(^2\)) | p-value |
|------------------------|---------------------|---------|
| Hypercalciuria         | 0.07                | 0.22    |
| Hypocitraturia         | 0.009               | 0.66    |
| Hyperuricosuria        | 0.02                | 0.45    |

**Figure 1.** Time to new event in MAP group at hypercalciuria.

**Figure 2.** Time to new event in MAP group at hypocitraturia.

**Figure 3.** Time to new event in MAP group at hyperuricosuria.
The relationship between MAP stones and urinary infection is well established. These stones are formed in urine containing urease-producing bacteria, resulting in ammonia saturation and high urinary pH. The excess of ammonia is associated with phosphate and magnesium ions, forming MAP complexes. The gold standard treatment for MAP stones is the complete elimination of calculi, because there is a chance of relapse due to bacteria stored in the calculi, even with urine sterilization through antibiotic treatment. However, even with MAP stone eradication through surgical procedures such as extracorporeal lithotripsy, flexible ureteroscopy, and percutaneous nephrolithotripsy, and urine sterilization, several authors reported recurrence of nephrolithiasis (20 to 47%) associated with urinary risk factors.

In the current study, hypocitraturia was found in 65.2% of patients over 3 months after being submitted to nephrectomy due to MAP stones. It is known that low levels of citrate due to metabolic deficiency may cause calcium precipitation. In renal tubular acidosis at CKD onset, intracellular acidosis also leads to a higher proximal tubular reabsorption of citrate, resulting in significant hypocitraturia. In our study, there was no difference in citraturia rate in patients with 1, 2, and 3 CKD grade ($p=0.45$). The high rate of hypocitraturia observed after nephrectomy might indicate that these patients are at risk of new stone formation due to metabolic cause and not only due to urinary infection. Also, we demonstrated that the treatment of hypocitraturia after the eradication of struvite stones equalizes stone recurrence rate to patients without hypocitraturia. Citrate is a known inhibitor of stone formation. Citrate reduces the availability of ionic calcium to interact with oxalate or phosphate in renal tubules, helping the inhibitory effects of macromolecular modulators on calcium oxalate crystallization processes. Also, it prevents crystal agglomeration and growth through its ability to bind to the crystal’s surface and it prevents adhesion of calcium oxalate to renal epithelial cells. However, the relatively low gastrointestinal tolerability of available alkali citrate preparations is the main limitation of its widespread usage. Jendle-Bengten et al., in a retrospective study, showed that only 62% of the patients adhered to potassium citrate treatment in the long term.
Hypercalciuria is an important risk factor for urinary calculi, occurring in 35-65% of calcium stones formers\(^\text{1}\). We identified hypercalciuria in 7.1% of patients in the MAP group, while 10.3% in CaOx group presented this abnormality. The low rates of hypercalciuria in the present study may be associated to the high proportion of patients with variable degrees of impairment of renal function, 71.4% in MAP group and 82.1% in CaOx group. Measures such as adequate fluid and sodium intake in addition to the use of thiazides may reduce the urinary calcium excretion\(^\text{12}\), which may prevent formation and growth of apatite crystal, having a positive impact in preventing these stones.

The small sample size, chemical stone analysis, and the impossibility of analyzing the nature of all recurrent urinary stones are shortcomings and limitations of this study. Chemical analysis is not the gold standard to determine urinary stone composition. However, we tried to reduce this limitation by including only “pure” CaOx and MAP stones. Therefore, mix stone composition would not contaminate our sample. However, we cannot determine the precision of the chemical analysis for “pure” stones because the method itself has poor reliability.

In conclusion, our study highlights the need for a 24-hour urinary assessment even in pure MAP stone formers after the eradication of stones. Patients submitted to nephrectomy due to pure MAP stones have similar risk of 24-hour urinary abnormalities as their CaOx counterparts. Moreover, when these 24-hour urinary abnormalities are treated, the risk of new stone-related events are similar to patients without any metabolic abnormalities.

**AUTHORS’ CONTRIBUTION**

Alexandre Danilovic, Thiago Augusto Cunha Ferreira, Samirah Abreu Gomes, Isabelo Akemi Wei, Fabio Carvalho Vicentini, Fabio Cesar Miranda Torricelli, Giovanni Scala Marchini, Eduardo Mazzucchi, Miguel Srougi, William Carlos Nahas contributed substantially to the conception or design of the study; collection, analysis, or interpretation of data; writing or critical review of the manuscript; and final approval of the version to be published.

**CONFLICT OF INTEREST**

The authors declare that they have no conflict of interest related to the publication of this manuscript.

**REFERENCES**

1. Pearle MS, Calhoun EA, Curhan GC, Project UDoA. Urologic diseases in America project: urolithiasis. J Urol. 2005;173(3):848-57.
2. Cee FL, Keck J, Norton ER. The natural history of calcium urolithiasis. JAMA. 1977;238(14):1519-23.
3. Scales CD, Smith AG, Hanley JM, Saigal CS, Project UDIA. Prevalence of kidney stones in the United States. Eur Urol. 2012;62(1):160-5.
4. Levy FL, Adams-Huet B, Pak CY. Ambulatory evaluation of nephrolithiasis: an update of a 1980 protocol. Am J Med. 1995;98(1):30-9.
5. Holmgren K. Urinary calculi and urinary tract infection. A clinical and microbiological study. Scand J Urol Nephrol Suppl. 1986;98:1-71.
6. Angerri O, López JM, Sánchez-Martín F, Millán-Rodríguez E, Rosales A, Villavicencio H. Simple Laparoscopic Nephrectomy in Stone Disease: Not Always Simple. J Endourol. 2016;30(10):1095-8.
7. Bichler KH, Eipper E, Naber K, Braun V, Zimmermann R, Lahme S. Urolithiasis. Int J Antimicrob Agents. 2002;19(6):488-98.
8. Iqbal MW, Shin RH, Youssef RB, Kaplan AG, Cabrera FJ, Hansa J, et al. Should metabolic evaluation be performed in patients with struvite stones? Urolithiasis. 2017;45(2):185-92.
9. Charlson ME, Pompeii P, Alex KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83.
10. Sankar A, Johnson SR, Beattie WS, Tait G, Wijesundera DN. Reliability of the American Society of Anesthesiologists physical status scale in clinical practice. Br J Anaesth. 2014;113(3):424-32.
11. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Fields S, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-12.
12. Parks JH, Coe FL. An increasing number of calcium oxalate stone events worsens treatment outcome. Kidney Int. 1994;45(6):1722-30.
13. Zisman AL. Effectiveness of Treatment Modalities on Kidney Stone Recurrence. Clin J Am Soc Nephrol. 2017;12(10):1699-708.
14. Carvalho M, Martin RL, Passos RC, Riella MC. Nephrectomy as a cause of chronic kidney disease in the treatment of urolithiasis: a case-control study. World J Urol. 2013;31(5):1141-5.
15. Skolarikos A, Straub M, Knoll T, Sarica K, Seitz C, Petrik A, et al. Metabolic evaluation and recurrence prevention for urinary stone patients: EAU guidelines. Eur Urol. 2015;67(4):750-63.
16. Paterson RF. Arguments for a comprehensive metabolic evaluation of the first-time stone former. Can Urol Assoc J. 2010;4(3):209-10.
17. Eisner BH, Sheth S, Dietle SP, Herrick B, Pais VM. Abnormalities of 24-hour urine composition in first-time and recurrent stone-formers. Urol. 2012;80(4):776-9.
18. Das P, Gupta G, Veld V, Awasthi R, Dua K, Malipedi H. Formation of struvite urinary stones and approaches towards the inhibition--A review. Biomed Pharmacother. 2017;96:361-70.
19. Cicerele F, Mango M, Cova GD, Merlo F, Maccatrozzo L. Metabolic evaluation in patients with infected nephrolithiasis: Is it necessary? Arch Ital Urol Androl. 2016;88(3):208-11.
20. Lingeman JE, Siegel YI, Steele B. Metabolic evaluation of infected renal lithiasis: clinical relevance. J Endourol. 1995;9(1):51-4.
21. Silverman DE, Stamey TA. Management of infection stones: the Stanford experience. Medicine (Baltimore). 1983;62(1):44-51.
22. Streem SB. Long-term incidence and risk factors for recurrent stones following percutaneous nephrolithotomy or percutaneous nephrolithotomy/endoscopy: the Stanford experience. Medicine (Baltimore). 1983;62(1):44-51.
23. Wall I, Hellgren E, Larsson L, Tiselius HG. Biochemical risk factors in patients with renal staghorn stone disease. Urol. 1986;28(5):377-80.
24. Resnick MI. Evaluation and management of infection stones. Urol Clin North Am. 1981;8(2):265-76.
25. Hesse A, Heimbach D. Causes of phosphate stone formation and the importance of metaphylaxis by urinary acidification: a review. World J Urol. 1999;17(5):308-15.
26. Hamm LL. Renal handling of citrate. Kidney Int. 1990;38(4):728-35.
27. Nicar MJ, Hill K, Pak CY. Inhibition by citrate of spontaneous precipitation of calcium oxalate in vitro. J Bone Miner Res. 1987;2(3):215-20.
28. Hess B, Zipperle I, Jaeger P. Citrate and calcium effects on Tamm-Horsfall glycoprotein as a modifier of calcium oxalate crystal aggregation. Am J Physiol. 1993;265(6 Pt 2):F784-91.
29. Sheng X, Jung T, Wesson JA, Ward MD. Adhesion at calcium oxalate crystal surfaces and the effect of urinary constituents. Proc Natl Acad Sci U S A. 2005;102(2):267-72.
30. Jendle-Bengten C, Tiselius HG. Long-term follow-up of stone formers treated with a low dose of sodium potassium citrate. Scand J Urol Nephrol. 2000;34(1):36-41.
31. Coe FL, Parks JH, Asplin JR. The pathogenesis and treatment of kidney stones. N Engl J Med. 1992;327(16):1141-52.
32. Coe FL, Worcester EM, Evan AP. Idiopathic hypercalciuria and formation of calcium renal stones. Nat Rev Nephrol. 2016;12(9):519-33.